Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
News|Articles|December 10, 2024
Therapeutic Advances in Alzheimer Disease
Author(s)Gary W. Small, MD
Key Takeaways
- Alzheimer's disease diagnosis has advanced significantly, incorporating brain scans and disease-modifying treatments.
- Challenges remain in the field, despite recent therapeutic advancements.
Do lifestyle interventions really work in Alzheimer disease and what are the underlying mechanisms? Learn more in this ACNP 2024 Annual Meeting session!
Advertisement
Gary Small, MD, shares information on his session "
His take home message: The ability to diagnose Alzheimer disease has improved, beyond brain scans all the way to disease modifying treatments. But unfortunately, there are challenges.
The varied presenters of this session cover lifestyle interventions, novel biomarkers, approved anti-amyloid drugs, and their associated controversies.
Are you attending this year's ACNP meeting? Let us know at
Dr Small is Chair of Psychiatry at Hackensack University Medical Center and Behavioral Health Physician in Chief at Hackensack Meridian Health.
Advertisement
Related to this article
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 3, 2026
2
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
3
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
4
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5